CEACAM5 and cancer: The developed prototype was tested with 14 live samples and the predicted concentrations of CEA were found to be excellent agreement with the commercially purchased ELISA kit. It is hoped that this research will lead to the development of portable and easy-to-use POC devices for detecting the cancer biomarkers which might subsequently lead to the early diagnosis of the terminal diseases.